Skip to main content

Table 2 Summary of the percentage of WHO type I tumors and outcome on overall survival

From: The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase iii randomized trials

Study

Trials included

Patients with WHO type I tumors

OR/HR/RR

  

CCRT

RT

Total (%)

2 yrs

3 yrs

5 yrs

Huncharek et al [2] 2002*

Al-Sarraf et al [1]

17/78

19/69

36/147 (24%)

0.16

0.16

0.16

Langendijk et al [3] 2004#

Al-Sarraf et al [1]

17/78

19/69

48/781 (6%)

NA

NA

0.48

 

Lin et al [8]

3/141

6/143

    
 

Chan et al [25]

2/174

1/176

    

Baujat et al [5] 2006#

Al-Sarraf et al [1]

17/78

19/69

41/716 (6%)

NA

NA

0.60

 

Chan et al [11]

2/174

1/176

    
 

Kwong et al [10]

a). Concurrent

b). Conc. +AC

1/53

0/57

1/55

0/54

    

Our study 2010§

Kwong et al [10]

1/110

1/55

5/1608 (0.31%)

0.63

0.76

0.74

 

Chan et al [11]

2/174

1/176

    
 

Wee et al [12]

0/111

0/110

    
 

Lee et al [13, 18]

0/172

0/176

    
 

Zhang et al [14]

0/59

0/56

    
 

Lee et al [15, 17]

0/51

0/42

    
 

Chen et al [16]

0/158

0/158

    
  1. Abbreviations: OR = Odds Ratio, HR = Hazard Ratio, RR = Relative risk (*used OR, #used HR,§used RR in the analysis), NA = Not Available